rPOC 0900
Alternative Names: rPOC-0900Latest Information Update: 12 Jul 2023
At a glance
- Originator EXUMA Biotech
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 11 Jul 2023 Discontinued - Preclinical for Solid tumours in USA (SC) prior to July 2023 (Exuma Biotech pipeline, July 2023)
- 12 Jan 2023 Preclinical trials in Solid tumours in USA (SC) before January 2023 (EXUMA Biotech pipeline, January 2023)